Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk ratio is reduced because of comorbidities and subs...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Kuiper, Rowan, Zweegman, Sonja, van Duin, Mark, van Vliet, Martin H., van Beers, Erik H., Dumee, Belinda, Vermeulen, Michael, Koenders, Jasper, van der Holt, Bronno, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette W. G., Beverloo, H. Berna, Stevens-Kroef, Marian, Levin, Mark-David, Broijl, Annemiek, Waage, Anders, Sonneveld, Pieter
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756986/
https://ncbi.nlm.nih.gov/pubmed/33351127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002838
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires